Yes, several therapeutic strategies aim to exploit DSBs in cancer cells. Radiotherapy and certain chemotherapeutic agents work by inducing DSBs to kill rapidly dividing cancer cells. Additionally, PARP inhibitors are designed to target cancer cells with defective DSB repair mechanisms, such as those with BRCA1 or BRCA2 mutations.
